Covid-19 roundup: Hydroxychloroquine fails again; Novavax lines up Warp Speed manufacturing partner
Hydroxychloroquine has failed in another major trial.
In a new study in the New England Journal of Medicine, 667 early-stage hospitalized patients were randomized to receive either standard of care, the anti-malaria drug, or the anti-malaria drug plus azithromycin. After 15 days, the patients in the different trial arms showed no difference in clinical improvement. Those in the hydroxychloroquine arm did, however, have more adverse events: namely a prolonged QT interval and an elevated number of liver enzymes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.